Heartworm disease continues to challenge shelters and veterinary practices nationwide, yet the cost and duration of recommended treatment remain major barriers to care. In the largest prospective randomized clinical trial ever conducted in canine heartworm treatment, involving 168 dogs with Class I and II heartworm disease, a compressed 2-dose melarsomine protocol paired with doxycycline, moxidectin, and prednisone achieved cure rates of over 95% and 100% survival, similar to traditional regimens.

This 2-dose "Lucky Dog Protocol" cut treatment costs and duration by more than 60%, shortening the interval from diagnosis to the final injection from 91 days to 15 days. That acceleration lets shelters move dogs into homes more quickly and makes the process easier for pet-owning families. For cases in which a more gradual worm kill is needed, the 3-dose protocol finishes injections by day 45 with a cure rate of 99%.

Attendees will learn how this evidence-drive spectrum-of-care model can broaden access, reduce relinquishment and euthanasia, and improve outcomes for heartworm-positive dogs in both shelters and private practices.
This will be a 60-minute presentation, followed by 30 minutes for Q&A.

Presenters:
Dr. Julie Levy
Director, Shelter Medicine Program, University of Florida
Dr. Linda Jacobson
Director, Science and Advancement, Toronto Humane Society

Mirah Horowitz CEO, Lucky Dog Animal Rescue

Read the full peer-reviewed publication in the Journal of the American Veterinary Medical Association: https://avmajournals.avma.org/view/journals/javma/264/12/javma.26.06.05…

This program is RACE approved for 1 hour of continuing education credit in jurisdictions which recognize RACE approval.

Event Location | Houston, Texas

Event Date | to

Advertisements